Literature DB >> 15790913

Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.

Hiroshi Tamura1, Kazuaki Miyamoto, Junichi Kiryu, Shinsuke Miyahara, Hideto Katsuta, Fumitaka Hirose, Kunihiro Musashi, Nagahisa Yoshimura.   

Abstract

PURPOSE: Recently, intravitreal injection of corticosteroids has been in wide use as a treatment for diabetic macular edema, and the outcomes have been favorable. However, the exact mechanism remains unclear. The hypothesis for the current study was that intravitreal corticosteroids may improve diabetic retinal edema by amelioration of blood-retinal barrier (BRB) breakdown, by inhibiting leukocyte stasis (leukostasis).
METHODS: Diabetes was induced in 6-week-old male Long-Evans rats by intraperitoneal injection of streptozotocin (75 mg/kg). Three weeks after induction of diabetes, intravitreal injection of dexamethasone (40 microg/10 microL) was performed. At 2 days after intravitreal injection, accumulated leukocytes were counted in vivo by acridine orange leukocyte fluorography, and BRB breakdown was evaluated by measurement of retinal vascular permeability. The mRNA expression and protein levels of intercellular adhesion molecule (ICAM)-1 in the retina were also studied.
RESULTS: The number of leukocytes accumulated in the retina, once increased in the diabetic group, was decreased by 31.6% (P = 0.0001) after dexamethasone injection. The level of BRB breakdown, also elevated in the diabetic group, was suppressed by 61.1% (P = 0.0046) after dexamethasone injection. The level of ICAM-1 mRNA expression and its protein, upregulated in the diabetic group, were downregulated by dexamethasone treatment by 70.0% (P < 0.0001) and 56.4% (P = 0.0003).
CONCLUSIONS: Intravitreal injection of corticosteroids improves diabetic retinal edema through inhibiting leukocyte recruitment in the diabetic retina.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790913     DOI: 10.1167/iovs.04-0905

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  72 in total

1.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Coat's-like exudation in rhodopsin retinitis pigmentosa: successful treatment with an intravitreal dexamethasone implant.

Authors:  L Patil; A J Lotery
Journal:  Eye (Lond)       Date:  2014-01-24       Impact factor: 3.775

3.  Intravitreal dexamethasone implant with retinal photocoagulation for adult-onset Coats' disease.

Authors:  Kshitiz Kumar; Pallavi Raj; Nisha Chandnani; Amar Agarwal
Journal:  Int Ophthalmol       Date:  2018-01-29       Impact factor: 2.031

4.  Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia.

Authors:  Akira Hirata; Masaru Inatani; Yasuya Inomata; Naoko Yonemura; Takahiro Kawaji; Megumi Honjo; Hidenobu Tanihara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-31       Impact factor: 3.117

5.  Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration.

Authors:  Chikako Yoshizawa; Wataru Saito; Shigeki Hirose; Hirokuni Kitamei; Kousuke Noda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2012-10-24       Impact factor: 2.447

6.  Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study.

Authors:  Ashish Sharma; Keerthi Bellala; Pankaj Dongre; Prahalad Reddy
Journal:  Int Ophthalmol       Date:  2019-08-03       Impact factor: 2.031

7.  Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors.

Authors:  Ziad F Bashshur; Abdallah M Terro; Christelle P El Haibi; Akaber M Halawi; Alexandre Schakal; Baha' N Noureddin
Journal:  Clin Ophthalmol       Date:  2008-06

8.  Involvement of A(1) adenosine receptors in osmotic volume regulation of retinal glial cells in mice.

Authors:  Antje Wurm; Stephan Lipp; Thomas Pannicke; Regina Linnertz; Katrin Färber; Peter Wiedemann; Andreas Reichenbach; Andreas Bringmann
Journal:  Mol Vis       Date:  2009-09-12       Impact factor: 2.367

9.  Intravitreal dexamethasone implants for diabetic macular edema.

Authors:  Alicia Pareja-Ríos; Paloma Ruiz-de la Fuente-Rodríguez; Sergio Bonaque-González; Maribel López-Gálvez; Virginia Lozano-López; Pedro Romero-Aroca
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

10.  Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas.

Authors:  Xinyuan Zhang; Shisan Bao; Donna Lai; Robert W Rapkins; Mark C Gillies
Journal:  Diabetes       Date:  2008-01-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.